Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ablynx

Ablynx
2001 FOUNDED
M&A STATUS
401-500 EMPLOYEES
M&A LATEST DEAL TYPE
$4.56B LATEST DEAL AMOUNT
Description

Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.

Website
Formerly Known As
MatchX
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • Technologiepark 21
  • 9052 Ghent
  • Belgium

+32 09 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ablynx’s full profile, request a free trial.

Ablynx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Merger/Acquisition 19-Jun-2018 $4.56B 00000 00.000 Completed Profitable
13. Merger/Acquisition 01-Dec-2017 00.000 00.000 Cancelled Profitable
12. PIPE 04-Oct-2017 00000 Completed Profitable
11. PIPE 24-Jan-2017 000.00 00000 00000 Completed Generating Revenue
10. Secondary Transaction - Open Market 03-Nov-2016 00000 Completed Profitable
9. PIPE 01-Jun-2016 000.00 00000 Completed Profitable
8. Secondary Transaction - Open Market 18-Oct-2013 00.000 00000 Completed Generating Revenue
7. 2PO 16-Mar-2010 000.00 00000 Completed Generating Revenue
6. IPO 07-Nov-2007 $108M $196M Completed Generating Revenue
5. Later Stage VC (Series C) 23-Aug-2006 $51.2M $88.2M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Ablynx Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lixte Biotechnology Holdings Corporation East Setauket, NY 0
00000 Venture Capital-Backed Cambridge, United Kingdom 000 00000 0000000000 0 00000
000000000 Venture Capital-Backed Vancouver, Canada 00 0000 00000000000 0000
000000 Venture Capital-Backed Lebanon, NH 000 000.00 00000000000 000.00
00000 000000 Venture Capital-Backed New York, NY 0000 0000000000 0 0000
To view this company’s complete list of competitors, request access »

Ablynx Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
Fidelity Management & Research Asset Manager Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ablynx Executive Team (17)

Name Title Board
Seat
Contact
Info
Edwin Moses Ph.D Chief Executive Officer
Wim Ottevaere Chief Financial Officer
Piet Houwen Chief Operating Officer
Robert Friesen Ph.D Chief Scientific Officer
Ludo Haazen MD Medical & Clinical Research Consultant

9 Former Executives

You’re viewing 5 of 17 executives. Get the full list »

Ablynx Board Members (9)

Name Representing Role Since Contact
Info
Catherine Moukheibir Self Independent Director & Board Member 000 0000
Geert Cauwenbergh Ph.D Self Board Member 000 0000
Remi Vermeiren Self Board Member 000 0000
Roger Perlmutter Ph.D Self Board Member 000 0000

5 Former Board Members

You’re viewing 4 of 9 board members. Get the full list »